• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Magenta raises $50m, inks partnership with Novartis for stem cell transplant drugs

May 2, 2017 By Sarah Faulkner

Magenta TherapeuticsMagenta Therapeutics said today that it closed a $50 million Series B round and licensed a clinical-stage program from Novartis (NYSE:NVS) to advance its stem cell transplantation platform. The company also inked a partnership deal with Be The Match BioTherapies.

Google’s venture arm, GV, led the financing round and was joined by existing investors, including Atlas Venture and Third Rock Ventures.

The company in-licensed Novartis’ MGTA-456, an investigational product designed to expand the number of cord blood stem cells used in transplants to improve outcomes. According to the agreement, Magenta can use the drug in “selected applications”.

Early results show that MGTA-456 can increase the number of umbilical cord blood stem cells.

Magenta is also collaborating with Be The Match BioTherapies, a subsidiary of the National Marrow Donor Program, to improve transplant medicines. Under the newly-established partnership, Magenta has access to Be The Match BioTherapies’ cell therapy delivery platform, industry relationships, clinical trial design and patient outcomes data.

“Magenta has quickly established itself as a nexus of innovation in stem cell science, catalyzing interest in this area of medicine with the recognition that improvements will have profound impact on patients,” CEO, president & co-founder Jason Gardner said in prepared remarks. “We aspire to accelerate products that could unleash the potential of transplantation to more patients, including those with autoimmune diseases, genetic blood disorders and cancer. The resounding interest in Magenta from such a high-quality set of investors is a testament to our solid progress since launch, including building a world-class team and a robust pipeline, and generating promising early data.”

Filed Under: Featured, Funding Roundup, Pharmaceuticals, Stem Cells, Wall Street Beat Tagged With: bethematchbiotherapies, magentatherapeutics, Novartis

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS